SCHEMBL6356591

SCHEMBL6356591

Cc1cccc(C)c1NC(=O)C(C)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.58
HSP90AA1 P07900 1/20 0.54
ALDH1A1 P00352 2/20 0.50
ANPEP P15144 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
CXCL8 P10145 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
NFKB1 P19838 1/20 0.49
POLB P06746 3/20 0.47
LMNA P02545 4/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPT P10636 3/20 0.46
SCN3A Q9NY46 2/20 0.46
CYP3A4 P08684 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12832472 0.86 ATM (0.60) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
SCHEMBL8973946 0.82 ATM (0.57) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
SCHEMBL28153117 0.82 ALDH1A1 (0.44) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
SCHEMBL6278395 0.82 ATM (0.66) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
Tocainide SCHEMBL15761 0.82 ATM (0.57) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
S-Tocainide SCHEMBL308742 0.82 ATM (0.57) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
SCHEMBL11427887 0.82 ATM (0.57) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
SCHEMBL13542699 0.81 ATM (0.55) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
SCHEMBL12994766 0.81 ATM (0.55) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1
Tocainide SCHEMBL9614374 0.81 ATM (0.55) ATMHSP90AA1ALDH1A1ANPEPL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960688-B2 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2005-11-01 US disclosed
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity ZENECA LIMITED 2004-01-15 US disclosed
US-6498275-B1 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2002-12-24 US disclosed
EP-1082110-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY AstraZeneca AB (SE) 2001-03-14 EP disclosed
WO-1999062506-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity PDHA1, PDK1, PDHB ATM 1204/4885HSP90AA1 483/4885ALDH1A1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.